Potent somatostatinreceptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens
The ED50 of J-2156 in rats for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws was 3.7 and 8.0 mg kg, respectively. J-2156 is a high potent, selective somatostatinreceptor type 4 (SST4 receptor) agonist with IC5
SSTR5 antagonist 1 is a selective, and orally available antagonist of somatostatinreceptor subtype 5 (SSTR5)(IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively).
SSTR5 antagonist 2 is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5),with potential to treat type 2 diabetes mellitus (T2DM).
SSTR5 antagonist 2 TFA is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5), with potential to treat type 2 diabetes mellitus (T2DM).
Vapreotide diacetate is a synthetic analog of somatostatin. It has analgesic activity most likely mediated through the blockade of the neurokinin-1 receptor (NK1R), the substance P (SP)-preferring receptor.
Pentetreotide is an indium-labeled somatostatin analog and can be used for nuclear medicine imaging. Pentetreotide is a diethylenetriaminopentaacetic conjugate of Octreotide. Somatostatinreceptor scintigraphy with Pentetreotide is effective in visualizin